Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CNSY Catalyst Timeline
Dated clinical, regulatory and corporate events for Cerenome, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cerenome, Inc.
Upcoming catalysts 2
Event history 34
Past FDA Catalysts and PDUFA Decisions
How CNSY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-13 | REYOBIQ (rhenium Re186 obisbemeda) | Phase 1 interim results | Phase 1 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 186RNL RadiopharmaceuticalsNCT01906385 | Glioma | Phase 1/2 | ACTIVE NOT_RECRUITING | 95 | Apr 1, 2027 | ||||||
| 186RNL RadiopharmaceuticalsNCT07061626 | Ependymoma | Phase 1 | RECRUITING | 56 | Mar 1, 2028 | ||||||
| 186RNL RadiopharmaceuticalsNCT05034497 | Leptomeningeal Metastasis | Phase 1/2 | COMPLETED | 61 | Oct 19, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every CNSY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| REYOBIQ™ | leptomeningeal metastases | 2026-11-16 | dose limiting toxicities: none; LM progression 3 months: 0/5; LM progression 6 months: 0/5; LM progression 9 months: 1/4; total administered activity: 79.2 mCi; doses administered: three 26.4 mCi dosesRead More | Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Guse KyleDirector | Option | 921 1,843 held | $0.00 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CNSY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CNSY for Q3 2026. | ||||
Ownership Trends
CNSY Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How CNSY ranks across every disease it competes in
CNSY News
Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting
Cerenome presented interim data from its ReSPECT-LM study at the SNO Annual Meeting. The study evaluates repeated dosing of REYOBIQ in leptomeningeal metastases. Notably, no dose-limiting toxicities were observed, and LM progression was not documented in most patients at three and six months. The findings support the feasibility of fractionated dosing.
Read more →Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress
Cerenome, Inc. reported its Q3 2026 financial results, highlighting the first revenue from its CNSide diagnostic platform and expansion of payer agreements. The company completed enrollment in its Phase 2 trial for recurrent glioblastoma and presented positive interim data for REYOBIQ. Despite a net loss increase, Cerenome is advancing its commercial and clinical programs.
Read more →Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
Cerenome, Inc. will host a conference call on November 16, 2026, to review REYOBIQ ReSPECT-LM clinical data presented at the SNO conference. The call will also include a commercial update on CNSide and the company's third quarter financial results. This event highlights Cerenome's focus on CNS oncology advancements.
Read more →Cerenome Appoints Director Ron Andrews as Chief Business Officer
Cerenome, Inc. appointed Ron Andrews as Chief Business Officer to enhance its business development and commercial strategy. Andrews, who has over 35 years of experience in diagnostics, will focus on expanding the CNSide Diagnostics platform and forming strategic partnerships. His leadership is expected to strengthen Cerenome's position in CNS oncology.
Read more →Cerenome Secures National In-Network Agreement with Aetna for CNSide®
Cerenome signed a national in-network agreement with Aetna for CNSide tests. The deal covers tumor cell enumeration and molecular profiling for central nervous system cancers. This addition brings 26 million members to Cerenome's payer network. Total covered lives now reach approximately 190 million across the US.
Read more →Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma
Cerenome has completed enrollment in the Phase 2 ReSPECT-GBM trial for REYOBIQ in recurrent glioblastoma. The trial enrolled 32 patients, with topline data expected in mid-2027. Interim results showed a 63% improvement in median overall survival compared to standard care. The company plans to discuss findings with the FDA after data analysis.
Read more →Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
Cerenome announced it will present interim data from the ReSPECT-LMM trial at the SNO Annual Meeting. The study evaluates REYOBIQ in patients with leptomeningeal metastases, a condition with no approved treatments. The company aims to progress to a Phase 2 study in 2027, potentially leading to accelerated approval.
Read more →Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
Cerenome announced new preclinical data for REYOBIQ, revealing its dual mechanism of action against cancer. The findings show that REYOBIQ, combined with anti-PD-1, enhances antitumor activity in ovarian cancer models. This combination improved median survival to 65 days and activated the immune response, suggesting potential for broader applications in oncology.
Read more →Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
Cerenome's subsidiary, CNSide Diagnostics, has secured an in-network agreement with Florida Blue, enhancing reimbursement for its CSF Tumor Cell Enumeration and Molecular Profile tests. This agreement adds approximately 6 million covered lives, bringing the total to 164 million. The move signifies a strategic expansion of CNSide's diagnostic capabilities for CNS oncology.
Read more →Cerenome Launches CNSide® CSF Molecular Profile Tests
Cerenome, Inc. has announced the launch of two new cerebrospinal fluid-based molecular profiling tests, CNSide® CSF Molecular Profile for solid tumors and hematologic malignancies. These tests will provide extensive DNA and RNA profiling, allowing for better characterization of CNS diseases. The launch aims to expand the patient population served and enhance the information available to physicians managing CNS cancers.
Read more →Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Cerenome, Inc. reported a positive business update for CNSide Diagnostics, highlighting $1.55 million in gross billings for Q3 2026. The company is on track to expand its testing menu and expects to cover approximately 200 million lives by early 2027. A favorable CMS pricing decision for its TCE Test is anticipated to take effect in January 2027.
Read more →Cerenome to Hold CNSide® Business Update Call on September 30, 2026
Cerenome, Inc. announced a business update call for its CNSide Diagnostics platform on September 30, 2026. The call will cover recent commercial developments, including billing and market access improvements. CEO Marc H. Hedrick highlighted the progress made since the platform's launch in early 2026 and aims to inform stakeholders about future growth plans.
Read more →Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
Cerenome, through its subsidiary CNSide Diagnostics, has secured an in-network agreement with Blue Cross Blue Shield of Michigan, enhancing coverage for its CNSide® CSF Tumor Cell Enumeration assay. This agreement, effective September 1, 2026, brings the total covered lives to approximately 158 million. The move is part of Cerenome's strategy to improve patient access and support physician adoption of its diagnostic tests.
Read more →Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
Cerenome, Inc. has appointed Samantha Fowlkes as Vice President and Head of Commercial Sales for CNSide Diagnostics. With over two decades of experience in oncology diagnostics, Fowlkes will lead the commercial expansion of the CNSide platform. Her appointment is seen as crucial for enhancing relationships within the oncology community and accelerating the adoption of CNSide's innovative diagnostic technologies.
Read more →Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
Cerenome, Inc. has announced a financing agreement with 3i, LP for up to $20 million, aimed at supporting the scale-up of its CNSide® cerebrospinal fluid assay platform. The initial funding has been received, with future tranches contingent on achieving specific milestones. This financing is expected to extend the company's cash runway into 2028.
Read more →Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
Cerenome presented key findings at the 2026 SNO/ASCO CNS Metastases Conference, highlighting the pharmacokinetics and safety of REYOBIQ in treating leptomeningeal metastases. The ongoing trials show promising safety signals and effective drug activity. Additionally, a cost-of-care analysis indicates that earlier detection and management could significantly reduce treatment costs for patients.
Read more →Cerenome Reports Second Quarter 2026 Financial Results and Business Update
Cerenome, Inc. reported its second quarter 2026 financial results, highlighting substantial progress in its CNS oncology platform and a successful rebranding from Plus Therapeutics. The company continues to enroll patients in multiple clinical trials for its lead therapeutic REYOBIQ, with no dose-limiting toxicities reported. However, the company experienced a significant increase in operating loss compared to the previous year.
Read more →Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
Cerenome signed an in-network agreement with Health Care Service Corporation for its CNSide assay. This deal adds 27.3 million covered lives to the company’s network. Total contracted coverage now exceeds 150 million lives. This result meets the firm’s full-year 2026 commercial payer coverage objective ahead of schedule.
Read more →Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform
Cerenome selected XiFin to manage billing for its CNSide platform. The company will start billing in the third quarter of 2026. This move addresses an accumulated backlog of tests from the previous period. The automated system aims to support higher volumes without increasing administrative costs.
Read more →Cerenome Launches as an Integrated CNS Oncology Company
Cerenome, formerly Plus Therapeutics, has launched as an integrated company focusing on CNS oncology. The company aims to enhance the detection, treatment, and understanding of CNS cancers through precision diagnostics, targeted therapeutics, and artificial intelligence. This strategic rebranding signifies a commitment to innovation in the oncology field.
Read more →